| Companies sponsors |
Regeneron (cemiplimab) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Asthma and Lung UK |
| |
Black Health Agency for Equality |
| |
Cancer Black Care |
| |
Cancer Equality |
| |
Helen Rollason Cancer Charity |
| |
Independent Cancer Patients Voice |
| |
Macmillan Cancer Support |
| |
Maggie’s Centres |
| |
Marie Curie |
| |
Oncogene - Driven Lung Cancer Patient Alliance UK. |
| |
Roy Castle Lung Cancer Foundation |
| |
South Asian Health Foundation |
| |
Specialised Healthcare Alliance |
| |
Tenovus Cancer Care |
| |
UK Lung Cancer Coalition |
| Professional groups |
Association of Anaesthetists |
| |
Association of Cancer Physicians |
| |
Association of Respiratory Nurse Specialists |
| |
Association of Surgeons of Great Britain and Ireland |
| |
British Geriatrics Society |
| |
British Institute of Radiology |
| |
British Oncology Pharmacy Association |
| |
British Psychosocial Oncology Society |
| |
British Society of Interventional Radiology |
| |
British Thoracic Oncology Group |
| |
British Thoracic Society |
| |
British Transplantation Society |
| |
Cancer Research UK |
| |
Lung Cancer and Mesothelioma Clinical Expert Group |
| |
Lung Cancer Nursing UK |
| |
National Heart and Lung Institute |
| |
NHS Blood and Transplant |
| |
Primary Care Respiratory Society |
| |
Royal College of Anaesthetists |
| |
Royal College of General Practitioners |
| |
Royal College of Nursing |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| |
Royal College of Surgeons |
| |
Royal Pharmaceutical Society |
| |
Royal Society of Medicine |
| |
Society and College of Radiographers |
| |
UK Clinical Pharmacy Association |
| |
UK Oncology Nursing Society |
| Assessment group |
Public Health Wales |
| |
UK Health Security Agency |
| Comparator companies |
Bristol Myers Squibb (paclitaxel) |
| |
Eli Lilly (pemetrexed) |
| |
Hospira UK (carboplatin, paclitaxel) |
| |
Medac (vinorelbine) |
| |
MSD (pembrolizumab) |
| |
Pierre Fabre (vinorelbine) |
| |
Pfizer (pemetrexed, cisplatin, carboplatin, gemcitabine) |
| |
Ranbaxy (gemcitabine, pemetrexed) |
| |
Roche (atezolizumab, bevacizumab) |
| |
Seacross Pharmaceuticals (paclitaxel) |
| |
Sandoz (cisplatin) |
| |
Synchrony Pharma (gemcitabine) |
| |
Teva UK (paclitaxel) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
Allied Health Professionals Federation |
| |
Board of Community Health Councils in Wales |
| |
British National Formulary |
| |
Care Quality Commission |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
National Association of Primary Care |
| |
National Pharmacy Association |
| |
NHS Confederation |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Cochrane Lung Cancer Group |
| |
Cochrane UK |
| |
Genomics England |
| |
Institute of Cancer Research |
| |
MRC Clinical Trials Unit |
| |
National Institute for Health Research |